USFDA Completes Inspection at OneSource Specialty Pharma's Sterile Product Division Facility
OneSource Specialty Pharma Limited has announced the completion of a routine current Good Manufacturing Practices (cGMP) inspection conducted by the United States Food and Drug Administration (USFDA).The USFDA inspected the Sterile Product Division (SPD) facility of OneSource Specialty Pharma, located in Bengaluru. The inspection took place from June 22, 2026, to June 30, 2026.
Following the conclusion of the routine cGMP review, the company received one observation. OneSource Specialty Pharma stated that it will provide a comprehensive response to the FDA regarding this observation within the stipulated timeframe.
ONESOURCE Stock Price Movement
Trading actively at 3:10 PM, Onesource Specialty Pharma Limited surges higher as its stock price climbs 2.62% to reach ₹1693.3. The equity maintains robust market interest, logging a traded volume of 71,022 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.